2. Search Result
Search Result
Results for "

MX-1

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Natural
Products

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0167
    Gynostemma Extract

    Ginsenoside C-MX1; Gypenoside IX

    		 Endogenous Metabolite Cancer
    Gynostemma Extract (Ginsenoside C-Mx1) is a natural product.
    Gynostemma Extract
  • HY-12098
    Verubulin hydrochloride

    MPC-6827 hydrochloride

    		 Microtubule/Tubulin Cancer
    Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood brain barrier permeable microtubule-disrupting agent, with potent and broad-spectrum in vitro and in vivo cytotoxic activities. Verubulin hydrochloride (MPC-6827 hydrochloride) exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. Verubulin hydrochloride (MPC 6827 hydrochloride) is a promising candidate for the treatment of multiple cancer types [1] .
    Verubulin hydrochloride
  • HY-123805
    KIN1400

    		HCV IFNAR Infection
    KIN1400 is a potent IRF3 activator. KIN1400 triggers IRF3-dependent innate immune antiviral genes (RIG-I, MDA5, IFIT1, and Mx1) and IFN-β expression. KIN1400 inhibits WNV and DV, two mosquito-borne members of the Flaviviridae and the genus Flavivirus. KIN1400 also inhibits HCV replication. KIN1400 induces innate antiviral immunity through a MAVS-IRF3 axis [1].
    KIN1400
  • HY-RS08859
    MX1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MX1 Human Pre-designed siRNA Set A contains three designed siRNAs for MX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MX1 Human Pre-designed siRNA Set A
    MX1 Human Pre-designed siRNA Set A
  • HY-RS24935
    Mx1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Mx1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mx1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Mx1 Rat Pre-designed siRNA Set A
    Mx1 Rat Pre-designed siRNA Set A
  • HY-RS18454
    Mx1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Mx1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mx1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Mx1 Mouse Pre-designed siRNA Set A
    Mx1 Mouse Pre-designed siRNA Set A
  • HY-N14478
    Saframycin Mx1

    		Bacterial Infection
    Saframycin Mx1 has anti-Gram-positive bacteria and Gram-negative bacteria effects [1].
    Saframycin Mx1
  • HY-14687
    (rac)-Talazoparib

    (rac)-BMN-673; (rac)-LT-673

    		 PARP Cancer
    (rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with Ki of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC50 of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC50 of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models [1].
    (rac)-Talazoparib
  • HY-155113
    PROTAC Hsp90α degrader 1

    		PROTACs HSP Cancer
    PROTAC Hsp90α degrader 1 (Compound X10g) is a selective PROTAC Hsp90α degrader. PROTAC Hsp90α degrader 1 can be used for breast cancer research. PROTAC Hsp90α degrader 1 inhibits the proliferation of MDA-MB-231, MDA-MB-468, MCF-7, MX-1 cells with IC50s of 51.48 μM, 16.46 μM, 8.93 μM, 11.95 μM respectively [1].
    PROTAC Hsp90α degrader 1
  • HY-121372
    Lactandrate

    		Estrogen Receptor/ERR Cancer
    Lactandrate is a D-high nitrogen steroid alkylating agent. It can interact with the ligand-binding domain (LBD) of estrogen receptor-alpha (ERα). Lactandrate has a growth inhibitory effect on breast cancer cells, with a GI50 value ranging from 5 to 65 μM. It shows anti-tumor activity in mouse breast tumors (MXT and CD8F1) as well as in human xenograft MX-1 [1].
    Lactandrate
  • HY-106031
    F-14512

    		Topoisomerase Cancer
    F-14512 is a targeted cytotoxic compound that utilizes the polyamine transport system (PTS) to selectively deliver polyamine-containing drugs to cancer cells. F-14512 combines an epipodophyllotoxin core that targets topoisomerase II with a spermine group that acts as a cell delivery vehicle, with improved selectivity for tumor cells. F-14512 exhibits significant cytotoxicity against cells with high PTS activity and demonstrates high potency in multiple human cell lines (median IC50=0.18 μM). In the MX1 breast tumor xenograft model, F-14512 exhibits potent antitumor activity [1].
    F-14512
  • HY-16106
    Talazoparib
    Maximum Cited Publications
    75 Publications Verification

    BMN-673; LT-673

    		 PARP Cancer
    Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity [1].
    Talazoparib
  • HY-160662
    BRD4-IN-5

    		Epigenetic Reader Domain Cancer
    BRD4-IN-5 (example 51) is a BRD4 inhibitor. The Ki values of the two BRD4 domains BDI_K57-E168 and BDII_E352-M457 are 9.7 nM and 16.1 nM, respectively. BRD4-IN-5 can be used in cancer research [1].
    BRD4-IN-5
  • HY-16124
    Canfosfamide

    TLK-286; TER286

    		 DNA-PK Apoptosis Cancer
    Canfosfamide (TLK-286, TER286) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis. Canfosfamide also inhibits the catalytic kinase activity of DNA-dependent protein kinase (DNA-PK). Canfosfamide produces an anticancer alkylating agent and a glutathione derivative after activation. Canfosfamide can be used to research malignancies [1] .
    Canfosfamide
  • HY-10617R
    Rucaparib phosphate (Standard)

    AG-014699 phosphate (Standard); PF-01367338 phosphate (Standard)

    		 PARP Cancer
    Rucaparib (phosphate) (Standard) is the analytical standard of Rucaparib (phosphate). This product is intended for research and analytical applications. Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].
    Rucaparib phosphate (Standard)
  • HY-10617
    Rucaparib phosphate
    40+ Cited Publications

    AG-014699 phosphate; PF-01367338 phosphate

    		 PARP Cancer
    Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research [1] .
    Rucaparib phosphate
  • HY-10617A
    Rucaparib
    40+ Cited Publications

    AG014699; PF-01367338

    		 PARP Cancer
    Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research [1] .
    Rucaparib
  • HY-102003A
    Rucaparib camsylate

    AG014699 camsylate; PF-01367338 camsylate

    		 PARP Cancer
    Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research [1] .
    Rucaparib camsylate
  • HY-102003
    Rucaparib monocamsylate
    40+ Cited Publications

    AG014699 monocamsylate; PF-01367338 monocamsylate

    		 PARP Cancer
    Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research [1] .
    Rucaparib monocamsylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: